EGFR Activating Mutation Clinical Trials
0 recruiting
Showing 1–4 of 4 trials
Recruiting
Not Applicable
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer with Leptomeningeal Disease
Leptomeningeal MetastasisEGFR Activating Mutation
British Columbia Cancer Agency10 enrolled1 locationNCT05257967
Recruiting
Phase 2
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NSCLCBrain MetastasesEGFR Activating Mutation
TYK Medicines, Inc420 enrolled1 locationNCT05948813
Recruiting
Phase 2
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728